Quick Answer
Edgewise Therapeutics, Inc. reported Operating Income Loss of -$191.41 million for the year ending 2025.
- Edgewise Therapeutics, Inc. showed a decrease of -20.5% in Operating Income Loss from 2024 to 2025.
- This data is from Edgewise Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$3.25 million | Q2 2020: -$3.96 million | Q3 2020: -$3.64 million | Q1 2021: -$6.86 million | Q2 2021: -$10.46 million | Q3 2021: -$13.08 million | Q1 2022: -$14.83 million | Q2 2022: -$16.49 million | Q3 2022: -$18.26 million | Q1 2023: -$25.70 million | Q2 2023: -$25.34 million | Q3 2023: -$29.45 million | Q1 2024: -$34.75 million | Q2 2024: -$38.11 million | Q3 2024: -$40.43 million | Q1 2025: -$45.96 million | Q2 2025: -$42.61 million | Q3 2025: -$46.86 million.
- Over the full 6 years of available data (2020 to 2025), Edgewise Therapeutics, Inc.'s Operating Income Loss has declined by 1,013.3%.
- Historical annual values: Fiscal year 2025: -$191.41 million | Fiscal year 2024: -$158.83 million | Fiscal year 2023: -$114.36 million | Fiscal year 2022: -$71.66 million | Fiscal year 2021: -$43.22 million | Fiscal year 2020: -$17.19 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: